Courier service EMS
Other transport services
Air India Post International
Payment in the bank on the invoice
Tasigna 200mg, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a probably therapy for chronic myelogenous leukemia (CML)
Tasigna 200mg is cancer drugs, which interfere with growth of the cancer cells.
Tasigna 200mg is a prescription medicine, which is used under the knowledge of medical oncologist.
Tasigna 200mg tablets are primarily indicated in the conditions like;
Adults with chronic and accelerated phase Philadelphia chromosome positive chronic myelogenous leukemia (Ph+ CML) resistant or intolerant to prior therapy that included Imatinib
Specifically connect with maximum affinity to ATP-binding site of BCR-ABL kinase prohibiting cell replication in cell lines and in primary Ph+ CML leukaemia cells
Effective against imatinib-resistant mutant forms of Bcr-Abl
Prevents PDGFR and c-Kit kinase
The high plasma concentration of Tasigna 200mg tablet is occurred within 3 hours after administration and bioavailability are 50%
The human plasma protein binding of the Tasigna 200mg is approximately 98%
The blood to serum ratio of nilotinib is 0.68
Tasigna 200mg is metabolized through CYP3A4 mediated oxidation
Nilotinib is the prime circulating component in the blood stream
The terminal half-life period of Tablet Tasigna 200mg is approximately 17 hours
The mean apparent clearance value is 29L/hr
Generally, the recommended dose of Tablet Tasigna should be taken as twice daily at time intervals of 12 hours.
Tasigna must be taken on an empty stomach
Food should not be taken for at least 1 hour after the dose is taken or 2 hours before the dose is taken
The patients, who are unable to take the Tasigna capsules, should be dispersed in one teaspoon of applesauce.
This mixture should be taken immediately within 15 minutes
Tasigna should be concomitant with hematopoietic growth factors such as erythropoietin or G-CSF
Also, with hydroxyurea or anagrelide
The prescribed dose of the Tasigna tablet in this condition is 300mg should be given orally as twice daily.
The prescribed dose is 400mg should be administered as orally twice daily
The recommended dose 230mg/m2 should be given orally twice daily
The maximum dose of Tablet Tasigna is 400mg.
Rash, Pruritus, alopecia, dry skin
Nausea, constipation, diarrhea, vomiting, upper abdominal pain, dyspepsia
Fatigue, pyrexia, asthenia, peripheral edema, face edema
Myalgia, arthralgia, muscle spasm, pain in extremity, back pain
Cough, oropharyngeal pain, dyspnea
Nasopharyngitis, upper respiratory tract infection, influenza, gastroenteritis
Eyelid edema, periorbital edema
While Tasigna 200mg interaction with strong CYP3A inhibitors leads to increase nilotinib concentrations compared to while using Tasigna 200mg alone
Tasigna 200mg interaction with strong CYP3A inducer leads to reduce nilotinib concentration
Tasigna 200mg with proton pump inhibitors: reduce Tasigna 200mg efficacy
Avoid interaction of Tasigna 200mg with drugs that may prolong the QT interval like anti-arrhythmic drugs
Tasigna 200mg do not used in the patients who are having;
Long QT syndrome
Tasigna 200mg may cause thrombocytopenia, neutropenia and anemia, so check blood counts periodically to reduce these complications
Care should be taking while using Tasigna 200mg in patient who are suffered with
Long QT syndrome
Pancreatitis and elevated lipase
Tumor lysis syndrome
Pregnancy category: D
Tasigna 200mg should not be used in pregnancy condition and women who become pregnant
Tasigna 200mg not recommended in breastfeeding mothers
Tasigna 200mg tablets should be stored at room temperature between 68oF to 77oF (20oC to 25oC)
Tasigna 200mg container should be keep away from heat, moisture and light
If patients missed to administer the dose of Tasigna 200mg should be taken within the time, otherwise the missed dose should be skipped and follow the next dosing schedule.
Вижте офертите за акции. Хубаво е да се спаси!View all